Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Bagella, Luigi ^a,c   Federico, Mario ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; ANTINEOPLASTIC AGENT; BELINOSTAT; BORTEZOMIB; CARBOPLATIN; DACINOSTAT; DEPSIPEPTIDE; DEPUDECIN; ENTINOSTAT; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; ISTODAX; MOCETINOSTAT; OXAMFLATIN; PACLITAXEL; PANOBINOSTAT; PDX 101; PLACEBO; PROTEINASE INHIBITOR; RETINOIC ACID; ROMIDEPSIN; TACEDINALINE; TRAPOXIN A; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BIPOLAR DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC FATIGUE SYNDROME; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONFUSION; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FLUSHING; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TUMOR; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INJECTION SITE REACTION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MANIA; MIGRAINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CANCER; NAUSEA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEPSIS; SEZARY SYNDROME; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; ST SEGMENT DEPRESSION; TESTIS CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; UTERINE CERVIX CANCER; ANIMAL; BLOOD DISEASE; NEOPLASM;

ANIMALS; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 79251541733     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/475641     Document Type: Review

References (101)

1. Allfrey V. G., Faulkner R., Mirsky A. E., Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proceedings of the National Academy of Sciences of the United States of America 1964 51 786 794
2. Allfrey V. G., Mirsky A. E., Structural modifications of histones and their possible role in the regulation of RNA synthesis Science 1964 144 3618 559
3. Lane A. A., Chabner B. A., Histone deacetylase inhibitors in cancer therapy Journal of Clinical Oncology 2009 27 32 5459 5468
4. Blander G., Guarente L., The Sir2 family of protein deacetylases Annual Review of Biochemistry 2004 73 417 435
5. Gu W., Roeder R. G., Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 1997 90 4 595 606
6. Martnez-Balbs M. A., Bauer U.-M., Nielsen S. J., Brehm A., Kouzarides T., Regulation of E2F1 activity by acetylation EMBO Journal 2000 19 4 662 671
7. Patel J. H., Du Y., Ard P. G., Phillips C., Carella B., Chen C.-J., Rakowski C., Chatterjee C., Lieberman P. M., Lane W. S., Blobel G. A., McMahon S. B., The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60 Molecular and Cellular Biology 2004 24 24 10826 10834
8. Chen L.-F., Fischle W., Verdin E., Greene W. C., Duration of nuclear NF-κB action regulated by reversible acetylation Science 2001 293 5535 1653 1657
9. Jeong J.-W., Bae M.-K., Ahn M.-Y., Kim S.-H., Sohn T.-K., Bae M.-H., Yoo M.-A., Song E. J., Lee K.-J., Kim K.-W., Regulation and destabilization of HIF-1 by ARD1-mediated acetylation Cell 2002 111 5 709 720
10. Wang C., Fu M., Angeletti R. H., Siconolfi-Baez L., Reutens A. T., Albanese C., Lisanti M. P., Katzenellenbogen B. S., Kato S., Hopp T., Fuqua S. A. W., Lopez G. N., Kushner P. J., Pestell R. G., Direct acetylation of the estrogen receptor hinge region by p300 regulates transactivation and hormone sensitivity Journal of Biological Chemistry 2001 276 21 18375 18383
11. Gaughan L., Logan I. R., Cook S., Neal D. E., Robson C. N., Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor Journal of Biological Chemistry 2002 277 29 25904 25913
12. Cohen H. Y., Lavu S., Bitterman K. J., Hekking B., Imahiyerobo T. A., Miller C., Frye R., Ploegh H., Kessler B. M., Sinclair D. A., Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis Molecular Cell 2004 13 5 627 638
13. Kovacs J. J., Murphy P. J. M., Gaillard S., Zhao X., Wu J.-T., Nicchitta C. V., Yoshida M., Toft D. O., Pratt W. B., Yao T.-P., HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Molecular Cell 2005 18 5 601 607
14. Yuan Z.-L., Guan Y.-J., Chatterjee D., Chin Y. E., Stat3 dimerization regulated by reversible acetylation of a single lysine residue Science 2005 307 5707 269 273
15. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., Matthias P., HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO Journal 2003 22 5 1168 1179
16. Bolden J. E., Peart M. J., Johnstone R. W., Anticancer activities of histone deacetylase inhibitors Nature Reviews Drug Discovery 2006 5 9 769 784
17. Whitesell L., Lindquist S. L., HSP90 and the chaperoning of cancer Nature Reviews Cancer 2005 5 10 761 772
18. Marks P. A., Dokmanovic M., Histone deacetylase inhibitors: discovery and development as anticancer agents Expert Opinion on Investigational Drugs 2005 14 12 1497 1511
19. Drummond D. C., Noble C. O., Kirpotin D. B., Guo Z., Scott G. K., Benz C. C., Clinical development of histone deacetylase inhibitors as anticancer agents Annual Review of Pharmacology and Toxicology 2005 45 495 528
20. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., Seiser C., Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression EMBO Journal 2002 21 11 2672 2681
21. Trivedi C. M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., Floss T., Goettlicher M., Noppinger P. R., Wurst W., Ferrari V. A., Abrams C. S., Gruber P. J., Epstein J. A., Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 activity Nature Medicine 2007 13 3 324 331
22. Mariadason J. M., HDACs and HDAC inhibitors in colon cancer Epigenetics 2008 3 1 28 37
23. Richon V. M., O'Brien J. P., Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment Clinical Cancer Research 2002 8 3 662 664
24. Yoo C. B., Jones P. A., Epigenetic therapy of cancer: past, present and future Nature Reviews Drug Discovery 2006 5 1 37 50
25. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M., Expression profile of class I histone deacetylases in human cancer tissues Oncology Reports 2007 18 4 769 774
26. Richon V. M., Sandhoff T. W., Rifkind R. A., Marks P. A., Histone deacetylase inhibitor selectively induces p21WAF1 expressjon and gene-associated histone acetylation Proceedings of the National Academy of Sciences of the United States of America 2000 97 18 10014 10019
27. Sandor V., Senderowicz A., Mertins S., Sackett D., Sausville E., Blagosklonny M. V., Bates S. E., P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 British Journal of Cancer 2000 83 6 817 825
28. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E. T., Yu Q., Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim Proceedings of the National Academy of Sciences of the United States of America 2005 102 44 16090 16095
29. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P. G., Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nature Medicine 2005 11 1 71 76
30. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E. M., Ferrara F., Bresciani F., Weisz A., De Lera A. R., Gronemeyer H., Altucci L., Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nature Medicine 2005 11 1 77 84
31. Zhang Y., Adachi M., Kawamura R., Imai K., Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis Cell Death and Differentiation 2006 13 1 129 140
32. Riggs M. G., Whittaker R. G., Neumann J. R., Ingram V. M., n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells Nature 1977 268 5619 462 464
33. Kruh J., Effects of sodium butyrate, a new pharmacological agent, on cells in culture Molecular and Cellular Biochemistry 1982 42 2 65 82
34. Candido E. P. M., Reeves R., Davie J. R., Sodium butyrate inhibits histone deacetylation in cultured cells Cell 1978 14 1 105 113
35. Sealy L., Chalkley R., The effect of sodium butyrate on histone modification Cell 1978 14 1 115 121
36. Boffa L. C., Vidali G., Mann R. S., Allfrey V. G., Suppression of histone deacetylation in vivo and in vitro by sodium butyrate Journal of Biological Chemistry 1978 253 10 3364 3366
37. Rastl E., Swetly P., Expression of poly(adenosine diphosphate-ribose) polymerase activity in erythroleukemic mouse cells during cell cycle and erythropoietic differentiation Journal of Biological Chemistry 1978 253 12 4333 4340
38. Marks P. A., Richon V. M., Rifkind R. A., Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells Journal of the National Cancer Institute 2000 92 15 1210 1216
39. Prince H. M., Bishton M. J., Harrison S. J., Clinical studies of histone deacetylase inhibitors Clinical Cancer Research 2009 15 12 3958 3969
40. Marks P. A., Breslow R., Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nature Biotechnology 2007 25 1 84 90
41. Piekarz R. L., Frye R., Turner M., Wright J. J., Allen S. L., Kirschbaum M. H., Zain J., Prince H. M., Leonard J. P., Geskin L. J., Reeder C., Joske D., Figg W. D., Gardner E. R., Steinberg S. M., Jaffe E. S., Stetler-Stevenson M., Lade S., Fojo A. T., Bates S. E., Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma Journal of Clinical Oncology 2009 27 32 5410 5417
42. Marks P. A., Xu W.-S., Histone deacetylase inhibitors: potential in cancer therapy Journal of Cellular Biochemistry 2009 107 4 600 608
43. Kim Y. B., Lee K.-H., Sugita K., Yoshida M., Horinouchi S., Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase Oncogene 1999 18 15 2461 2470
44. Tan J., Cang S., Ma Y., Petrillo R. L., Liu D., Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents Journal of Hematology and Oncology 2010 3, article 5
45. Olsen E. A., Kim Y. H., Kuzel T. M., Pacheco T. R., Foss F. M., Parker S., Frankel S. R., Chen C., Ricker J. L., Arduino J. M., Duvic M., Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma Journal of Clinical Oncology 2007 25 21 3109 3115
46. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J. H., Reilly J. F., Ricker J. L., Richon V. M., Frankel S. R., Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 2007 109 1 31 39
47. Olsen E., Duvic M., Breneman D., Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL) Journal of Clinical Oncology 2008 26
48. Crump M., Coiffier B., Jacobsen E. D., Sun L., Ricker J. L., Xie H., Frankel S. R., Randolph S. S., Cheson B. D., Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Annals of Oncology 2008 19 5 964 969
49. Kirschbaum M., Zain J., Popplewell L., Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin's lymphoma: a California Cancer Consortium study Journal of Clinical Oncology 2007 25. abstract no. 18515
50. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W. G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V. R., Randolph S. S., Hardwick J. S., Reilly J. F., Chen C., Ricker J. L., Secrist J. P., Richon V. M., Frankel S. R., Kantarjian H. M., Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 2008 111 3 1060 1066
51. Ramalingam S. S., Parise R. A., Ramananthan R. K., Lagattuta T. F., Musguire L. A., Stoller R. G., Potter D. M., Argiris A. E., Zwiebel J. A., Egorin M. J., Belani C. P., Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies Clinical Cancer Research 2007 13 12 3605 3610
52. Ramalingam S. S., Maitland M. L., Frankel P., Argiris A. E., Koczywas M., Gitlitz B., Thomas S., Espinoza-Delgado I., Vokes E. E., Gandara D. R., Belani C. P., Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer Journal of Clinical Oncology 2010 28 1 56 62
53. Bradley D., Rathkopf D., Dunn R., Stadler W. M., Liu G., Smith D. C., Pili R., Zwiebel J., Scher H., Hussain M., Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium Cancer 2009 115 23 5541 5549
54. Vansteenkiste J., Van Cutsem E., Dumez H., Chen C., Ricker J. L., Randolph S. S., Schffski P., Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer Investigational New Drugs 2008 26 5 483 488
55. Blumenschein G. R. Jr., Kies M. S., Papadimitrakopoulou V. A., Lu C., Kumar A. J., Ricker J. L., Chiao J. H., Chen C., Frankel S. R., Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer Investigational New Drugs 2008 26 1 81 87
56. Kachhap S. K., Rosmus N., Collis S. J., Kortenhorst M. S.Q., Wissing M. D., Hedayati M., Shabbeer S., Mendonca J., Deangelis J., Marchionni L., Lin J., Hti N., Nortier J. W. R., Deweese T. L., Hammers H., Carducci M. A., Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor PLoS ONE 2010 5 6, article e11208 1 12
57. Miller K. M., Tjeertes J. V., Coates J., Legube G., Polo S. E., Britton S., Jackson S. P., Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining Nature Structural and Molecular Biology 2010 17 9 1144 1151
58. Folkvord S., Ree A. H., Furre T., Halvorsen T., Flatmark K., Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status International Journal of Radiation Oncology, Biology, Physics 2009 74 2 546 552
59. Ree A. H., Dueland S., Folkvord S., Hole K. H., Seierstad T., Johansen M., Abrahamsen T. W., Flatmark K., Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study The Lancet Oncology 2010 11 5 459 464
60. Sandor V., Bakke S., Robey R. W., Kang M. H., Blagosklonny M. V., Bender J., Brooks R., Piekarz R. L., Tucker E., Figg W. D., Chan K. K., Goldspiel B., Fojo A. T., Balcerzak S. P., Bates S. E., Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clinical Cancer Research 2002 8 3 718 728
61. Byrd J. C., Marcucci G., Parthun M. R., Xiao J. J., Klisovic R. B., Moran M., Lin T. S., Liu S., Sklenar A. R., Davis M. E., Lucas D. M., Fischer B., Shank R., Tejaswi S. L., Binkley P., Wright J., Chan K. K., Grever M. R., A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood 2005 105 3 959 967
62. Fouladi M., Furman W. L., Chin T., Freeman B. B. III, Dudkin L., Stewart C. F., Krailo M. D., Speights R., Ingle A. M., Houghton P. J., Wright J., Adamson P. C., Blaney S. M., Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report Journal of Clinical Oncology 2006 24 22 3678 3685
63. Klimek V. M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J. J., Pandolfi P. P., Nimer S. D., Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes Clinical Cancer Research 2008 14 3 826 832
64. Schrump D. S., Fischette M. R., Nguyen D. M., Zhao M., Li X., Kunst T. F., Hancox A., Hong J. A., Chen G. A., Kruchin E., Wright J. J., Rosing D. R., Sparreboom A., Figg W. D., Steinberg S. M., Clinical and molecular responses in lung cancer patients receiving Romidepsin Clinical Cancer Research 2008 14 1 188 198
65. Stadler W. M., Margolin K., Ferber S., McCulloch W., Thompson J. A., A phase II study of depsipeptide in refractory metastatic renal cell cancer Clinical Genitourinary Cancer 2006 5 1 57 60
66. Parker C., Molife R., Karavasilis V., Romidepsin (FK228), a histone heacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC) Journal of Clinical Oncology 2007 25. abstract no. 15507
67. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., Newsome W. M., Miller W. H. Jr., Rousseau C., Kalita A., Bonfils C., Dubay M., Patterson T.-A., Li Z., Besterman J. M., Reid G., Laille E., Martell R. E., Minden M., Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 2008 112 4 981 989
68. Crump M., Andreadis C., Assouline S., Rizzieri D., Wedgwood A., Mclauglin P., Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD01013: interim results from a phase II study Journal of Clinical Oncology 2008 26. abstract no. 8528
69. Bociek R. G., Kuruvilla G., Pro B., Wedgwood A., Li Z., Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) Journal of Clinical Oncology 2008 26. abstract no. 8507
70. Siu L. L., Pili R., Duran I., Messersmith W. A., Chen E. X., Sullivan R., MacLean M., King S., Brown S., Reid G. K., Li Z., Kalita A. M., Laille E. J., Besterman J. M., Martell R. E., Carducci M. A., Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors Journal of Clinical Oncology 2008 26 12 1940 1947
71. Hurwitz H., Nelson B., O'Dwyer P. J., Chiorean E. G., Gabrail N., Li Z., Phase I/II: the oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors Journal of Clinical Oncology 2008 26. abstract no. 4625
72. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., Bhalla K., A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clinical Cancer Research 2006 12 15 4628 4635
73. Duvic M., Vanaclocha F., Bernengo M. G., Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-Cell Lymphoma (CTCL) Journal of Clinical Oncology 2008 26. abstract no. 8555
74. Gimsing P., Hansen M., Knudsen L. M., Knoblauch P., Christensen I. J., Ooi C. E., Buhl-Jensen P., A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia European Journal of Haematology 2008 81 3 170 176
75. Steele N. L., Plumb J. A., Vidal L., Tjrrnelund J., Knoblauch P., Rasmussen A., Chean E. O., Buhl-Jensen P., Brown R., Evans T. R. J., DeBono J. S., A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors Clinical Cancer Research 2008 14 3 804 810
76. Mackay H. J., Hirte H., Colgan T., Covens A., MacAlpine K., Grenci P., Wang L., Mason J., Pham P.-A., Tsao M.-S., Pan J., Zwiebel J., Oza A. M., Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours European Journal of Cancer 2010 46 9 1573 1579
77. Kummar S., Gutierrez M., Gardner E. R., Donovan E., Hwang K., Eun J. C., Lee M.-J., Maynard K., Kalnitskiy M., Chen A., Melillo G., Ryan Q. C., Conley B., Figg W. D., Trepel J. B., Zwiebel J., Doroshow J. H., Murgo A. J., Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies Clinical Cancer Research 2007 13 18 5411 5417
78. Gore L., Rothenberg M. L., O'Bryant C. L., Schultz M. K., Sandler A. B., Coffin D., McCoy C., Schott A., Scholz C., Eckhardt S. G., A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas Clinical Cancer Research 2008 14 14 4517 4525
79. Juergens R. A., Vendetti F., Coleman B., Sebree R. S., Rudek M. A., Belinsky S. A., Phase I trial of 5-azacitidine (AC) and SNDX-275 in advanced lung cancer (NSCLC) Journal of Clinical Oncology 2008 26. abstract no. 19036
80. Chavez-Blanco A., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Cetina L., Candelaria M., Cantu D., Gonzalez-Fierro A., Garcia-Lopez P., Zambrano P., Perez-Plasencia C., Cabrera G., Trejo-Becerril C., Angeles E., Duenas-Gonzalez A., Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study Molecular Cancer 2005 4, article 22
81. Atmaca A., Al-Batran S.-E., Maurer A., Neumann A., Heinzel T., Hentsch B., Schwarz S. E., Hvelmann S., Gttlicher M., Knuth A., Jger E., Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial British Journal of Cancer 2007 97 2 177 182
82. Candelaria M., Gallardo-Rincn D., Arce C., Cetina L., Aguilar-Ponce J. L., Arrieta., Gonzlez-Fierro A., Chvez-Blanco A., de la Cruz-Hernndez E., Camargo M. F., Trejo-Becerril C., Prez-Crdenas E., Prez-Plasencia C., Taja-Chayeb L., Wegman-Ostrosky T., Revilla-Vazquez A., Dueas-Gonzlez A., A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Annals of Oncology 2007 18 9 1529 1538
83. Kuendgen A., Knipp S., Fox F., Strupp C., Hildebrandt B., Steidl C., Germing U., Haas R., Gattermann N., Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia Annals of Hematology 2005 84 supplement 1 61 66
84. Soriano A. O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W. G., Ouzounian S., Quezada A., Pierce S., Estey E. H., Issa J.-P. J., Kantarjian H. M., Garcia-Manero G., Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 2007 110 7 2302 2308
85. Garcia-Manero G., Kantarjian H. M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., Rytting M., Wierda W. G., Ravandi F., Koller C., Xiao L., Faderl S., Estrov Z., Cortes J., O'Brien S., Estey E., Bueso-Ramos C., Fiorentino J., Jabbour E., Issa J.-P., Phase 1/2 study of the combination of 5-aza- 2′ -deoxycytidine with valproic acid in patients with leukemia Blood 2006 108 10 3271 3279
86. Swanton C., Caldas C., Molecular classification of solid tumours: towards pathway-driven therapeutics British Journal of Cancer 2009 100 10 1517 1522
87. Jagannath S., Dimopoulos M. A., Lonial S., Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma Leukemia Research 2010 34 9 1111 1118
88. Weber D., Badros A., Jagannath S., Vorinostat plus Bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience Blood 2008 112. abstract no. 871
89. Imanishi R., Ohtsuru A., Iwamatsu M., Iioka T., Namba H., Seto S., Yano K., Yamashita S., A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy Journal of Clinical Endocrinology and Metabolism 2002 87 10 4821 4824
90. Piekarz R. L., Sackett D. L., Bates S. E., Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy Cancer Journal 2007 13 1 30 39
91. Rasheed W. K., Johnstone R. W., Prince H. M., Histone deacetylase inhibitors in cancer therapy Expert Opinion on Investigational Drugs 2007 16 5 659 678
92. Page J. G., Rodman L., Heath J. E., Tomaszeqski J. E., Smith A. C., Effect of infusion rate on the toxicity of depsipeptide (NCS-63-176) in Beagle Dogs Proceedings of the American Association for Cancer Research 1995 36. abstract no. 2193
93. Page J. G., Rodman L., Heath J. E., Thomaszewski J. E., Smith A. C., Comparison of toxicity of depsipeptide (NSC-630176) in dogs and rats Proceedings of the American Association for Cancer Research 1996 37. abstract no. 2549
94. Piekarz R. L., Frye A. R., Wright J. J., Steinberg S. M., Liewehr D. J., Rosing D. R., Sachdev V., Fojo T., Bates S. E., Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma Clinical Cancer Research 2006 12 12 3762 3773
95. Marshall J. L., Rizvi N., Kauh J., Dahut W., Figuera M., Kang M. H., Figg W. D., Wainer I., Chaissang C., Zhaoyang Li M., Hawkins M. J., A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer Journal of Experimental Therapeutics and Oncology 2002 2 6 325 332
96. Whittaker S., McCulloch W., Robak T., International multicenter Phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): interim report Journal of Clinical Oncology 2006 24. abstract no. 3062
97. Balasubramanian S., Verner E., Buggy J. J., Isoform-specific histone deacetylase inhibitors: the next step? Cancer Letters 2009 280 2 211 221
98. Chang S., McKinsey T. A., Zhang C. L., Richardson J. A., Hill J. A., Olson E. N., Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development Molecular and Cellular Biology 2004 24 19 8467 8476
99. Montgomery R. L., Potthoff M. J., Haberland M., Qi X., Matsuzaki S., Humphries K. M., Richardson J. A., Bassel-Duby R., Olson E. N., Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice Journal of Clinical Investigation 2008 118 11 3588 3597
100. Fotheringham S., Epping M. T., Stimson L., Khan O., Wood V., Pezzella F., Bernards R., La Thangue N. B., Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis Cancer Cell 2009 15 1 57 66
101. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., Duvic M., Kerr D. J., La Thangue N. B., HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy Proceedings of the National Academy of Sciences of the United States of America 2010 107 14 6532 6537